Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly.

It binds to the epidermal growth factor receptor (EGFR).

[4] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).

[5][6][3] It was counterproductive in non-squamous non-small-cell lung carcinoma.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.